Gilead & Merck’s Phase 2 Data Show Promise for Oral Weekly HIV Regimen
Gilead Sciences and Merck (MSD outside the U.S. and Canada) have shared promising Phase 2 clinical study results for...
Gilead & Merus Team Up for Groundbreaking T-Cell Engagers
Gilead Sciences, Inc. and Merus N.V. have entered into a research collaboration to develop novel dual tumor-associated antigen (TAA)...
EU Validates Datopotamab Apps for Lung & Breast Cancer
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan,...
Real-World Data Back Veklury for Hospitalized COVID-19 Patients
Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces...
Gilead’s HIV Pipeline Targets Needs & Advances Public Health
Gilead Sciences has revealed a range of positive data from its HIV research pipeline, showcasing its innovative treatment strategies....
AbbVie, OSE Partner for Novel Anti-Inflammatory Antibody
AbbVie Inc. and OSE Immunotherapeutics SA have announced a strategic partnership to develop OSE-230, a monoclonal antibody in the...
SCRI & AstraZeneca Forge Alliance for Cancer Research Tech
Sarah Cannon Research Institute (SCRI), a global leader in conducting community-based clinical trials, has announced a collaboration with AstraZeneca...
FDA Priority Review for Epcoritamab in Refractory Lymphoma
Genmab A/S and AbbVie have received Priority Review from the FDA for epcoritamab-bysp, a bispecific antibody for the treatment...
Mandara III Data: Fasenra Aids EGPA Remission, NEJM Reports
Positive results from the MANDARA Phase III trial for FASENRA® (benralizumab) in patients with eosinophilic granulomatosis with polyangiitis (EGPA)...
Biktarvy by Gilead: FDA Approval for Resistant HIV Cases
Gilead Sciences, Inc. has announced the FDA’s approval of an expanded indication for Biktarvy® to treat people with HIV...